Provider of a healthcare insights platform designed to reduce the global burden of disease through an actionable healthc
Provider of a healthcare insights platform designed to reduce the global burden of disease through an actionable healthcare map.
Enterprise Systems (Healthcare)📍 New York, NYFounded 2014
Current Valuation
$3.3B
as of 2021-Q1
UNICORN
QL Price
$986.6M
-70% vs last round
QuantLogix's current estimate for Komodo Health, published 2026-09-27 — below the last disclosed round of $3.3B (2021-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$3.3B
2021-Q1
weight 0.02
Secondary market print
$897.6M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Komodo Health since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Komodo Health, 2026-09-27 (480529b4de200f3d).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Komodo Health going public?
No. Komodo Health is private and has not filed to go public. There is no S-1 on file.
What is Komodo Health's valuation in 2026?
Komodo Health is valued at $3.3B as of 2021-Q1, set by its Series E ($220M, Mar 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Komodo Health filed an S-1?
No public S-1 is on file for Komodo Health.
How much has Komodo Health raised?
Komodo Health has raised $327.5M in total, most recently a Series E of $220M in Mar 2021.
Is Komodo Health publicly traded — can you buy Komodo Health stock?
No. Komodo Health is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Komodo Health on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2014
HQ
New York, NY
Employees
785
Total Raised
$327.5M
Last Round
Series E — $220M (Mar 2021)
IPO Status
private
Fundraising Status
Series E · $220M · 5y 6mo ago
privateTotal raised $327.5M
Secondary Market
Implied price / share
$13.86
Last round price / share
$51
vs last round
-72.8%
Open interest
2
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series E
$220M
Mar 2021
—
$3.3B
Talent Signal
Hiring trend
▼ Hiring downtrend
-17% vs 2026-08
Open roles
29
via greenhouse
Product-build share
34%
engineering, research, product, design
Trajectory
strengthening
balanced build + GTM — 34% builders vs 66% go-to-market/G&A — scaling both sides.
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Principal Product Manager, AI ProductsSenior Data Platform EngineerSenior Data Product ManagerSenior Forward Deployed Engineer, AISenior Infrastructure EngineerSenior Software Engineer (Salesforce)
Counted from Komodo Health's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareInformation TechnologyPredictive AnalyticsSoftwareArtificial Intelligence
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q1. Refreshed quarterly.